Page 1259 - Basic _ Clinical Pharmacology ( PDFDrive )

Index 1245

Thiopurine S-methyltransferase (TPMT) Thyroid–pituitary relationships, 690, 691f Tocilizumab, 653, 995
characteristics of, 78t Thyroid-simulating hormone (TSH, Tofacitinib, 656–657, 987
genetic polymorphisms in, 67t, 69 thyrotropin), 668f, 668–669, Tolazamide, 758, 768t. See also
pharmacogenomics of, 77t, 79t, 81 670t Sulfonylureas
Thioridazine. See also Antipsychotic agents Thyroid storm, 699 Tolbutamide, 758, 768t. See also
description of, 511–524, 513f, 528t Thyrotoxicosis Sulfonylureas
psychosis treated with, 513f, 514–515, amiodarone-induced, 700 Tolcapone, 500, 508t
520t. See also Antipsychotic manifestations of, 691, 694t Tolerance, 38, 576–578
agents in pregnancy, 700 alcohol (ethanol), 400
Thiotepa, 953, 953f, 955t. See also Thyrotropin-releasing hormone (TRH), inducer, 71
Alkylating agents 669, 669t nitrates and nitrites, 200–201
Thiothixene, 511–524, 513f, 515, 515t, Thyroxine, 687. See T 4 opioid, 559, 561t, 564–565
528t. See also Antipsychotic Tiagabine, 420–421, 433t, 437t sedative-hypnotic drugs, 389–390
agents Ticagrelor, 620 Tolmetin, 644f, 645t, 649. See also
Thioxanthenes, 511–524, 513f, 528t. See Ticlopidine, 620 Nonsteroidal anti-inflammatory
also Antipsychotic agents Tics, 493, 505–506, 508t drugs (NSAIDs)
derivatives of, 513f, 515, 515t Tigecycline, 817–818, 824t Tolnaftate, 1073
structure of, 513f Tiludronate Tolterodine, 131, 135t. See also Muscarinic
Thorn apple, 124. See also Atropine; on bone homeostasis, 779–781 receptor blockers
Muscarinic receptor blockers Paget’s disease of bone treated with, 789 Toluene, 1010
Threshold limit values (TLVs), 1004 Time course Tolvaptan, 308, 317t, 682, 684t
Thrombin, 609–610, 611f of drug accumulation, 46f, 46–47 diuresis uses of, 268–269, 273t
Thrombin inhibitors of drug effect, 48–49 heart failure treated with, 224
direct, 617–618 cumulative, 49 Tonic-clonic seizures, generalized,
indirect, 612f, 612–614. See also Heparin delayed, 49 413–421. See also Antiseizure
Thrombocytopenia, 592 immediate, 48–49, 49f drugs; Seizures
Thrombolytics, 619, 619b of drug elimination, 46f Topiramate
Thrombophlebitis, ascending, 619 Time-dependent killing, 910 migraine headache prophylaxis using, 291
Thrombopoietin (TPO), 604, 997t Timing of samples, for drug concentration seizures treated with, 427–428, 433t, 436t
Thrombosis, 342, 343f measurement, 53–54 tremor treated with, 503
Thromboxane A 2 (TXA 2 ), 259, 324, 329, Timolol, 163f, 164t, 166, 170t. See also Topiramate + phentermine, 289b, 290t
608, 619 b-receptor antagonist drugs Topotecan, 962t, 964
Thromboxanes, 327–331 Tinidazole Torcetrapib, 638
Thymidylate synthase (TS), 958 amebiasis treated with, 929t, 929–930, Toremifene, 737, 737f
Thyroid drugs, 689–692, 701t. See also 930f Torsade de pointes, 233f, 234b, 237f
Antithyroid drugs; specific drug description of, 896, 902t Torsemide, 262t, 262–264, 273t
basic pharmacology of, 689–692 Tinzaparin, 612. See also Heparin Total systemic clearance, 45
clinical pharmacology of, 696–698 Tiotropium, 126f, 135t. See also Muscarinic Tourette’s syndrome
hypothyroidism, 694t, 696t, 696–698 receptor blockers (antagonists) antipsychotics for, 519
myxedema coma, 697 chronic obstructive pulmonary disease description of, 505–506, 508t
preparations available, 701t treated with, 130, 354, 359 Toxaphenes, 1010t, 1010–1011, 1013f
Thyroid gland structure of, 126f Toxic dose, median (TD 50 ), 37
abnormal stimulators of, 689 Tipranavir, 873t, 882 Toxic effects, selectivity and, 39–40
autoregulation of, 688f, 689 Tiprolisant, 285 Toxic epidermal necrosis (TEN), 83, 83t
function of Tirofiban, 621 Toxicity, 3, 13, 13t. See also specific drugs
on drug metabolism, 72 Tissue factor pathway inhibitor, 610 Toxic multinodular goiter, 699
evaluation of, 688–689, 690t Tissue factor-VIIa complex, 610–611, 611f Toxicodynamics, 1035
iodide metabolism in, 687 Tissue plasminogen activator (t-PA), 611, Toxicokinetics, 1035
Thyroid hormones, 689–692 611f, 619 Toxicology, 1003–1019
biosynthesis of, 687–688, 688f Tissue schizonticides, 917, 918f air pollutants, 1006–1009
chemistry of, 689f, 689–690 Tizanidine. See also Sympathomimetics, carbon monoxide, 1006–1007, 1007t
effects of, 691, 692t direct-acting nitrogen oxides, 1007t, 1008
mechanism of action of, 690–691, 693f description of, 149, 153, 154t ozone and other oxides, 1007t,
metabolism of, peripheral, 688, 689f spasmolytic actions of, 486f, 487, 489t 1008–1009
pharmacokinetics of, 689t, 690, 692t T-lymphocyte-associated antigen 4 permissible exposure limit values of,
preparations of, 691–692 (CTLA-4), 980 1007t
transport of, 688 T lymphocytes, 979, 979f, 980, 981f sources of, 1006
Thyroid neoplasms, 700 Tobramycin, 826, 827f, 831, 833, 833t sulfur dioxide, 1007, 1007t